Omniscope’s Post

The future of human health lies at the intersection of cutting-edge science and transformative technology—a convergence PICI is driving full force. We look forward to tomorrow's Converge Summit hosted by Biocom California, where PICI Board Member Margo Georgiadis, CEO of Montai Therapeutics/CEO-Partner at Flagship Pioneering, will kick off discussions in a keynote fireside chat with insitro CFO/CBO Mary Rozenman, PhD. They will explore how AI/ML and advanced computing can drive breakthroughs in drug discovery and precision medicine. At PICI, we're breaking down barriers and fostering deep collaboration across disciplines and institutions to accelerate the development of breakthrough immune therapies. Our researchers use CRISPR, AI/ML, bioinformatics and novel tech platforms to develop smarter, more personalized treatments for cancer. Through this convergence, we continue to advance our mission to turn all cancers into curable diseases. Don't miss Margo's vision for harnessing life science and technology collaboration to improve human health on Wednesday at 10:10 a.m. PT. Learn more: https://lnkd.in/dFkGidfW    

Don’t Miss This! Dive into the future of biomedicine with us next week in #SanDiego! Join us next week at the Festival of Biologics San Diego for an interesting panel discussion brought to you by Business Location Switzerland and Swissnex in San Francisco. What’s on the Agenda?  We’re diving deep into RNA technology and its role in developing breakthrough antibody therapies to fight critical illnesses such as cancer, Alzheimer's, and autoimmune diseases. Get ready to explore the latest trends, groundbreaking research, and the challenges ahead with top experts from both #Switzerland and the #US. Meet Our Esteemed Panelists: - Rudi Micheletti, spearheading Biology and Functional Genomics at Haya Therapeutics. - Susan Szathmary, MD, PhD, leading the charge at the Open Biopharma Research and Training Institute. - Dimitrios G. Zisoulis, the mind behind RNA Therapeutics at Johnson & Johnson. - Gene Yeo, a pioneering Professor at UCSD’s Dept of Cellular and Molecular Medicine and a key figure at the UCSD Institute for Genomic Medicine. The panel discussion "Decoding the Dark Genome through RNA Technology: Ways Forward with Swiss and US Innovation’” will be moderated by the insightful Julio de Unamuno IV, Executive Director of HomeLab at UCSD. Don’t miss out on this opportunity to gain insights from leading minds in the field and discover how Swiss and US expertise is paving the way forward in biotech innovation. #biotechnology #RNAtechnology #innovation #whyswitzerland #FestivalofBiologics #healthcare #pharma

AlphaProteo: Revolutionizing Protein Design for Health and Biology! 🧬🤖 How can we accelerate the discovery of new drugs and deepen our understanding of diseases? Meet Google DeepMind #AlphaProteo, an AI system that generates novel proteins to bind to target molecules, unlocking new possibilities in research and development. #AlphaProteo has already demonstrated success, generating protein binders with 3 to 300 times better binding affinity than existing methods for key targets like #VEGF-A, involved in cancer, and the #SARS-CoV-2 spike protein. This breakthrough in protein design is transforming fields like drug development, biosensors, and disease diagnostics, paving the way for faster, more efficient research! Explore how AlphaProteo is setting new standards in biology and health research ➡️ 38/100 #AI #ProteinDesign #HealthInnovation #AIForGood #Biotech #100DayChallenge #DrugDevelopment

🌟 Breaking Barriers in Disease Modeling: Innovative Technologies Paving the Way Forward 🌟 At ARRAYS FOR CELL NANODEVICES, SL - A4CELL, we are driven by the need to overcome limitations in traditional disease models. 🧫💡 Our senior strategic liaison, Julio Martin, shared at the ELRIG Drug Discovery 2024 event how our SPAchip technology is transforming live-cell imaging. Unlike traditional approaches that provide only static snapshots, #SPAchip enables continuous, real-time observation of live cells without harming them. This breakthrough is essential for understanding dynamic physiological changes over time, bringing new insights into diseases like cancer and neurodegeneration. We are proud to be at the forefront of this innovation, offering researchers a tool that enhances accuracy and reproducibility in disease modeling. 🚀 Let’s revolutionize the future of healthcare together! 🌐 #Biotech #Innovation #DiseaseModeling #A4Cell #SPAchip #DrugDiscovery #LifeSciences #technologynetworks

Rejuvenation Startup Summit in Berlin has begun! The first talk was from Otto Kanzler from Rockfish Bio. They're working on new generation senolytics and biomarker development to measure the impact of senescent cells on our bodies. The we all know, the 1st generation of senolytics encountered significant side effects, compounded by the challenge of lacking non-invasive clinical biomarkers to assess senescent cell load and the absence of monitoring tools for therapy. To address these issues, the team has pinpointed a target pathway and gathered initial data from mouse models. Their leading candidate has demonstrated promising outcomes, enhancing activity levels and reducing frailty index in older mice, thereby extending both healthspan and lifespan. And the mice were indeed old, - 34 m.o! Their strategy revolves around targeting PLA2 and arachidonic acid signalling, leveraging the notion that elevated arachidonic acid levels prompt apoptosis. However, intracellular levels of AA in healthy cells return to normal once senescent cells are eliminated. Moreover, they are actively developing biomarkers to quantify senescent cell burden. #senescence #senolytics #aging #rejuvenationstartupsummit

Exciting news! Join us at the #BiotechWeekBoston (BWB) Awards next Monday, September 23, where we’re honored to be among the finalists for the Start-up of the Year Award! We’re also thrilled to announce that our CEO, Liang Schweizer, is named a Finalist for the prestigious Lifetime Achievement Award.     Under Liang’s visionary leadership, our passionate team has advanced a diverse portfolio of cutting-edge immunotherapies targeting cancers and autoimmune diseases, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS®) translational platform represents a significant leap forward in precision medicine, allowing for more tailored therapies for individual patients and maximizing clinical success rates.    Click here to register for the event: https://lnkd.in/ehi_EvwZ   #biotech #immunotherapy #innovation #DrugIntelligenceScience #leadership #BWB #StartupoftheYear #PrecisionMedicine #AI #CancerTherapies

🚀 It’s a wrap for NUVISAN's Our Science series! As our Science Series comes to a close after a wonderful couple of months, we want to take a moment to reflect on the journey we've shared. Throughout this series, we have delved into various fascinating topics and explored groundbreaking discoveries. We hope that each post has sparked your curiosity, and perhaps even inspired a deeper interest in the sciences. It has been our pleasure to bring you engaging content and insightful discussions. While our Science Series may be concluding, our commitment to delivering informative and captivating content continues. Stay tuned for more exciting topics and updates! 🤝 💫 🚀 Impurity Profiling: https://lnkd.in/eDysdwsm 💻 Bioinformatic Analysis: https://lnkd.in/eJwH6sHA 🚀 Single Cell RNA-sequencing: https://lnkd.in/ewkhnCmT 🌈 Spectral Flow Cytometry: https://lnkd.in/efwMvFr8 🎯 Targeted Protein Degradation (TPD): https://lnkd.in/eb-e-pYF 🚀 Organoids as a new tool for drug screening: https://lnkd.in/eVygivqK 🎨  Cell Painting: https://lnkd.in/esWNMirX 📯 NUVISAN's Game-Changing Compound Libraries: https://lnkd.in/etMX6Uhr 🚀 Developmental Metabolite Identification - Part II: https://lnkd.in/eAi6hEkn 💊 eSource Data Collection in Clinical Trials: https://lnkd.in/ewa9pKfZ 💊 Developmental Metabolite Identification - Part I: https://lnkd.in/exkZ7UHB 🔬 Revolutionizing Therapeutics with LNPs: https://lnkd.in/ec2hNyeJ 🔬 In vitro drug release test (IVRT) solutions: https://lnkd.in/emuzjD8z 🚀 Pinpoint your drug candidate´s CYP450 induction potential: https://lnkd.in/ehEB2y_y 🚀 Cryo-Electron Microscopy(Cryo-EM): https://lnkd.in/ewGvngEJ #OurScience #NUVISAN #theScienceCRO #drugdiscovery #drugdevelopment

Great to have this summary of Nuvisan's Science Series, which nicely illustrates our consultative approach from target to clinic as well as specific capabilities on that path. The range of topics covered includes genomics, proteomics & bioinformatics, cellular assay systems, structural biology & screening, pharmacology, degrader platforms, LNPs, MetID & DDI, impurity testing, formulation, IVRT and manufacturing, and eSource Data Collection, so something for everyone really 😊!

This article highlights the collaboration between ACT Genomics, a cancer genomic profiling leader, and LSI Medience in Japan to advance personalized medicine services. The Memorandum of Understanding signifies their joint effort to explore opportunities in genomic and clinical testing services specifically tailored to the Japanese healthcare landscape. Both companies aim to integrate genomic profiling into clinical research practices to provide personalized and effective information for Japanese researchers, ultimately setting new standards in precision medicine. Hashtags: #PersonalizedMedicine #GenomicProfiling #Collaboration #PrecisionMedicine #HealthcareInnovation Read more here: https://lnkd.in/esdzu3Vu BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

We’re thrilled to announce our participation in the Vancouver AI Showcase, happening alongside the prestigious NeurIPS Conference – a global hub for cutting-edge AI innovation. Hosted by AInBC and Vancouver.dev at Northeastern University Vancouver, this event will highlight the diversity of AI companies in BC. At Diagen, we’re harnessing AI models to pioneer advancements in protein design tackling the health market in everything from therapeutics and vaccines to biosensors and in vitro diagnostics. If you’re in town for NeurIPS or passionate about the convergence of AI and health, join us at the showcase to learn more! #ProteinRevolution #GenerativeAI #NeurIPS2024 #HealthInnovation #DiagenAI